Portal de Periódicos da CAPES

Self-amplifying RNA vaccine protects mice against lethal Ebola virus infection

2022; Elsevier BV; Volume: 31; Issue: 2 Linguagem: Inglês

10.1016/j.ymthe.2022.10.011

1525-0024

Verena Krähling, Stephanie Erbar, Alexandra Kupke, Sara S. Nogueira, Kerstin C. Walzer, Hendrik Berger, Erik Dietzel, Sandro Halwe, Cornelius Rohde, Lucie Sauerhering, Letícia Aragão-Santiago, Jorge Moreno Herrero, Sonja Witzel, Heinrich Haas, Stephan Becker, Uǧur Şahin,

SARS-CoV-2 and COVID-19 Research

Emerging and re-emerging viruses, such as Zaire Ebola virus (EBOV), pose a global threat and require immediate countermeasures, including the rapid development of effective vaccines that are easy to manufacture. Synthetic self-amplifying RNAs (saRNAs) attend to these needs, being safe and strong immune stimulators that can be inexpensively produced in large quantities, using cell-free systems and good manufacturing practice. Here, the first goal was to develop and optimize an anti-EBOV saRNA-based vaccine in terms of its antigen composition and route of administration. Vaccinating mice with saRNAs expressing the EBOV glycoprotein (GP) alone or in combination with the nucleoprotein (NP) elicited antigen-specific immune responses. GP-specific antibodies showed neutralizing activity against EBOV. Strong CD4